The Federal Hemp Rules Arrive on Two Different Dates, and Only One of Them Was Delayed

Section 781 of Public Law 119-37, signed November 12, 2025, rewrote the federal definition of hemp and set its own effective date 365 days later, November 12, 2026. Section 2019 of the Continuing Appropriations and Extensions Act, 2027, signed September 2, 2026 as Public Law 119-103, provides that until December 11, 2026 the section 781 amendments apply only to two narrow categories of product.

Those two categories are intermediate and final hemp-derived cannabinoid products containing cannabinoids that are not capable of being naturally produced by a Cannabis sativa L. plant. Everything else in the new definition, including the 0.4 milligram total THC per container limit on finished products, begins December 11, 2026.

Two patient populations are affected on two different clocks. People using synthesized hemp cannabinoids such as hexahydrocannabinol lose their federal footing on November 12, 2026. People using full-spectrum CBD oil, hemp-derived THC beverages, and most hemp gummies are reached a month later, on December 11, 2026, by a per-container ceiling low enough to exclude the great majority of products now sold.

Neither date changes what is in the bottle. A product that remains lawful is not thereby tested, accurately labeled, or suited to a particular patient, and a product that becomes unlawful does not become pharmacologically different on the day the statute reaches it. The clinical questions are the same ones as before: what is the exact product, how much, how often, by what route, and alongside which medications.

Section 781 replaces the 2018 Farm Bill test, which looked only at delta-9 THC, with a total tetrahydrocannabinols standard that includes tetrahydrocannabinolic acid, still capped at 0.3 percent on a dry weight basis. That change alone converts a large amount of material that passed the old test into material that does not pass the new one, because THCA converts to delta-9 THC when heated and the old rule did not count it.

The definition then lists exclusions. Viable seeds from a plant above the total THC threshold are out. Intermediate hemp-derived cannabinoid products are out if they contain cannabinoids that a cannabis plant cannot naturally produce, or cannabinoids the plant can produce that were synthesized or manufactured outside it, or more than 0.3 percent combined total of THC and other cannabinoids with similar effects. Intermediate products that are marketed or sold as a final product, or sold directly to a consumer, are also excluded.

Final hemp-derived cannabinoid products are excluded on the same two synthesis grounds, and separately if they contain more than 0.4 milligrams combined total per container of THC and cannabinoids with similar effects. Container is defined as the innermost wrapping in direct contact with the product at retail, which means a bottle, not a shipping carton. Drug products approved under section 505 of the Federal Food, Drug, and Cosmetic Act are carved out of the definition of hemp-derived cannabinoid product entirely, so an FDA-approved cannabidiol prescription is not affected by any of this.

H.R. 6500 passed the Senate 90 to 6 on August 8, 2026, was agreed to by the House 370 to 48 on September 1, and was signed on September 2 as Public Law 119-103. Section 2019 of that law runs one sentence long. Until December 11, 2026, the section 781 amendments apply only with respect to products described in paragraphs (1)(C)(ii)(I) and (1)(C)(iv)(I) of the amended definition.

Those paragraph references are the whole story. They point to intermediate products and final products containing cannabinoids that are not capable of being naturally produced by a Cannabis sativa L. plant. That category takes effect on the original November 12, 2026 date. Hexahydrocannabinol sits inside it under the government’s stated position, which is why the federal picture for HHC did not improve when the extension passed.

The adjacent category, cannabinoids the plant can produce but that were synthesized or manufactured outside it, was not carved out and therefore moves to December 11. That is where converted delta-8 THC generally sits, since delta-8 occurs in the plant in trace amounts and commercial delta-8 is made from cannabidiol in a reactor. A patient using an HHC vape and a patient using a delta-8 gummy are on different dates, one month apart, for reasons that have nothing to do with dose or risk.

A 30 milliliter bottle of full-spectrum CBD oil sold as compliant under the 0.3 percent standard can hold on the order of 90 milligrams of total THC. The new rule allows 0.4 milligrams in that same bottle. A single 5 milligram hemp THC seltzer exceeds the per-container figure by more than tenfold. The cap is not a tightening of the existing standard so much as a different kind of standard, measured in absolute milligrams per package rather than as a percentage of plant weight.

The executive branch has said as much in writing. Executive Order 14370, signed December 18, 2025 and published at 90 FR 60541, states that some full-spectrum CBD products will once again be controlled as marijuana under the Controlled Substances Act when section 781 takes effect, because they contain THC levels above the per-container threshold, and it directs officials to work with Congress to update the definition so that patients retain access to appropriate full-spectrum products. That instruction was issued nine months ago and the statutory text has not changed.

For a patient, the practical consequence lands on December 11, 2026 rather than November 12. For a clinician, the counseling consequence lands sooner, because patients are making purchasing and stockpiling decisions now based on headlines that report a delay without saying what was delayed.

Hemp is not a controlled substance because it is carved out of the Controlled Substances Act definition of marijuana, and THC in hemp is carved out of the separate control of tetrahydrocannabinols. Narrowing the hemp definition operates as an exception to those exceptions. A product that no longer meets the definition is not merely unregulated, it is regulated as marijuana or as THC, which is Schedule I.

One partial exception exists. A DEA final rule published April 28, 2026 at 91 FR 22714 placed marijuana-containing drug products in Schedule III where they are FDA-approved or where they are handled under a state-issued license to manufacture, distribute, or dispense marijuana for medical purposes. A hemp-derived gummy sold at a gas station falls under neither description, so nothing in that rule softens where these products land.

How aggressively any of this gets enforced is a separate question from what the statute says. The Congressional Research Service has noted that the Department of Justice does not comprehensively enforce the Controlled Substances Act against marijuana, for resource reasons and because of a longstanding appropriations rider covering state-legal medical use. Patients should not read enforcement discretion as permission, and clinicians should not describe it as legality.

Section 781 also directed the Food and Drug Administration, within 90 days of enactment, to publish a list of all cannabinoids known to be capable of being naturally produced by a cannabis plant, a list of THC class cannabinoids known to occur naturally in the plant, a list of other known cannabinoids with similar effects to THC class cannabinoids, and additional specificity about the term container. That deadline fell in February 2026.

In its August 17, 2026 update on the hemp definition, the Congressional Research Service recorded that the lists had not been published. No such publication appears in the Federal Register as of today. The result is that the exclusion taking effect on November 12 turns on a question, which cannabinoids a plant cannot naturally produce, that the agency charged with answering it has not answered on the record.

This matters at the counter and in the exam room. A retailer deciding what to pull, a manufacturer deciding what to reformulate, and a clinician asked whether a specific cannabinoid is on the wrong side of the line are all working without the reference the statute promised them.

The same law that moved most of the hemp provisions to December 11, 2026 funds the federal government until December 11, 2026. Section 106 of its continuing appropriations division ties the availability of funds to that date. The hemp deadline was not set by anyone reasoning about cannabinoid chemistry. It was set by attaching the question to the next spending fight.

Several bills would change the underlying law. Two would delay the new definition for roughly two more years, H.R. 7010 and S. 3686, along with H.R. 7024. One would repeal the 2025 changes, H.R. 6209. The Lawful Hemp Protection Act, H.R. 9830, introduced July 22, 2026 by Representatives Andy Barr and Angie Craig, would replace the restriction with a regulated framework including a 1 percent total THC allowance, a minimum purchase age of 21, and federal testing and labeling rules. The Beverage Regulatory Parity Act, H.R. 10079, introduced August 10, 2026 by Representatives Beth Van Duyne and Greg Landsman, would build an alcohol-style system for qualifying hemp beverages with a 5 milligram serving cap.

None of those bills has been reported out of committee. Each sits at referral. The realistic path for any of them, on the record as it stands, is attachment to whatever funding measure Congress takes up before December 11, which is the same mechanism that produced both the original restriction and the partial delay.

The statutory text is not in dispute and can be read directly. Section 781 carries its own effective date, section 2019 of the September law is a single sentence with two paragraph citations in it, and both are published in full by the Government Publishing Office. On the question of what the law says and when each part starts, the record is as solid as legal evidence gets.

Everything downstream of the text is softer. How the Department of Justice will enforce it, how the Food and Drug Administration will define the cannabinoid categories once it publishes, how manufacturers will reformulate, and whether Congress moves again before December 11 are all open. Read the dates as fixed and the consequences as forecast.

The December 11 date is the least durable element here. It exists because a continuing resolution needed a date, and the same law sets federal funding to lapse on it. A further delay, a partial repeal, or a replacement framework could ride the next spending vehicle, and any of those would move the line again. Reporting that treats December 11 as settled is overreading a temporary instrument.

The November 12 category is also less crisp than it sounds. Whether a given cannabinoid is capable of being naturally produced by a cannabis plant is a scientific question with a moving literature, and the agency directed to publish the reference list has not done so. In the meantime the category is being applied by inference from earlier agency positions rather than from a published list.

The statute says nothing about whether any hemp-derived product helps anyone. It sets definitional boundaries and effective dates. A product that stays inside the definition has not been shown to be safe, effective, or accurately labeled, and a product that falls outside it has not been shown to be harmful.

It also does not settle state law. States may restrict more than the federal definition does, and several already do. A patient in a state with its own hemp THC limit is governed by that limit regardless of what happens in November or December, and a product that becomes federally noncompliant does not become available anywhere by virtue of a federal delay.

This sits on top of a year of state activity moving in the same direction at different speeds. Texas, Ohio, Virginia, and Louisiana have each set their own rules for hemp THC products, sometimes with limits well above the federal 0.4 milligram per container figure, which means a beverage that is lawful under a state statute can fall outside the federal hemp definition on December 11 without a word of state law changing.

It also interacts with the slow federal reconsideration of cannabis itself. Marijuana-containing drug products that are FDA-approved or handled under a state medical license moved to Schedule III in April 2026, while products that fall out of the hemp definition are headed toward Schedule I treatment. The legal distance between a licensed medical product and a hemp shop product is widening, not narrowing, which is an argument for routing patients toward supervised, tested supply.

The patients who will be hurt by this are not the ones the law was written about. The intoxicating hemp market that prompted Congress to act is a real problem, and I have seen enough poorly labeled gas station products to understand why legislators reached for a blunt instrument. But the 0.4 milligram per container figure does not distinguish between a vape engineered for effect and a full-spectrum CBD oil that an older patient with arthritis has been taking for three years because the trace THC in it makes the cannabidiol work better for her.

So the conversation I am having in clinic is practical rather than political. If you use a full-spectrum product, know its actual total THC per container, not per serving, and understand that the number on your bottle is probably above the December threshold. If you use a synthesized cannabinoid such as HHC, the relevant date is November 12, and the product quality argument against it was already strong before any of this. And if you are a patient who qualifies for a state medical program, this is a good year to have that conversation, because a tested supply chain with a clinician attached to it is not affected by any of these dates.

Two dates. November 12, 2026 for intermediate and final products containing cannabinoids a cannabis plant cannot naturally produce. December 11, 2026 for the rest of the new hemp definition, including the 0.4 milligram total THC per container ceiling that reaches most full-spectrum CBD and essentially every hemp THC beverage. Neither date has been changed since the September 2 law, and neither one makes any product safer or better labeled.

Carry forward the two dates and the container figure, because those are in the statutory text and can be checked. Hold loosely everything about enforcement, agency interpretation, and what Congress does before the funding deadline, because those are forecasts. The single most useful thing a reader can do this month is find out how many total milligrams of THC are in the container of whatever they are currently taking.